New cell therapy offers hope for tough blood cancers
Disease control
Recruiting now
This study tests a new treatment called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) that has come back or not responded to other treatments. Participants receive one infusion of CTD402 and are monitored for safety and how w…
Phase: PHASE1, PHASE2 • Sponsor: BIOHENG THERAPEUTICS US LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC